[Immunocorrective therapy of patients with chronic active liver diseases of a viral nature].
A study of the effect of immunocorrective drugs on the clinicobiochemical and immunological indices of patients with chronic active liver diseases of viral nature made it possible to work out criteria for administration of levamisole (the absence of the cytolytic syndrome, the presence of immunodeficiency in the system of cellular immunity and disturbance of immunoregulation), prednisolone, the combination of prednisolone and azathioprine, and d-Penicillamine (severe hepatocellular insufficiency, the presence of autoimmune reactions and disturbance of immunoregulation). The treatment of patients with chronic active diseases with immunocorrective drugs required a strict individual approach taking account of clinicobiochemical, immunological and morphological indices.
D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000276:immunology*; D006521:Hepatitis, Chronic / Q000276:immunology*; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use; D008231:Lymphopenia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D007978:Levamisole; D011239:Prednisolone; D010396:Penicillamine; D001379:Azathioprine
Immunokorrigiruiushchaia terapiia bol'nykh khronicheskimi aktivnymi zabolevaniiami pecheni virusnoĭ prirody.